Is Bristol-Myers Squibb a Buy?
Bristol-Myers Squibb (NYSE: BMY) isn't having a great year. The big pharma stock has spent most of 2019 in negative territory. Many investors weren't happy with the decision to acquire Celgene (NASDAQ: CELG). And BMS has experienced some clinical-study disappointments for its blockbuster cancer drug, Opdivo.
But is Bristol-Myers Squibb still a smart pick for long-term investors? Let's look at the reasons to consider buying the stock and the reasons to avoid it.
Image source: Getty Images.
Source Fool.com
